Dr. Lal PathLabs Limited

“Dr. Lal PathLabs is a structurally sound, capital-light diagnostics compounder with genuine brand and network moat in North India, net-cash balance sheet, and a decades-long reinvestment runway in one of the world's most underpenetrated healthcare markets. However, at 37x forward earnings and a PEG of 2.5–3x, the market has already priced in a decade of above-average execution, leaving an expected 10-year return of only 2–2.5x (8–10% CAGR) — adequate but not compelling for new capital. The permanent impairment risk is low (no leverage, clean governance, structurally growing market), but the opportunity cost risk is real: multiple compression alone could erase 3–5 years of earnings growth. New investors should track for a better entry around INR 1,250–1,300 (~30x forward); existing holders should hold without adding.”